ReviewSensors (Basel, Switzerland)2026
Strategies for Multiplexing Plasmonic Biosensing.
Review in Sensors (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Plasmonic biosensing technologies have emerged as powerful analytical tools for sensitive and label-free characterisation of biomolecular interactions and complex samples. The increasing demand for comprehensive molecular profiling has accelerated the development of multiplexing strategies that enable simultaneous analysis of multiple analytes and molecular interactions. This Feature Paper examines multiplexing through the complementary spatial, spectral, and temporal dimensions of multiplexing, together with their hybrid combinations and associated analytical trade-offs. Compared with other optical biosensing approaches, including interferometric, photonic, and fluorescence-based sensing platforms, plasmonic biosensors remain attractive owing to their combination of label-free detection, real-time interaction monitoring, sensitive interfacial analysis, and compatibility with multiplexed assay formats. This Feature Paper critically discusses current multiplexing strategies, focusing primarily on surface plasmon resonance (SPR), imaging SPR (SPRi), localised SPR (LSPR), surface-enhanced Raman scattering (SERS), and related nanoplasmonic biosensing approaches, together with recent advances in surface biofunctionalisation, antifouling interfaces, and molecular recognition strategies. Representative applications in biomedical diagnostics and non-clinical settings are highlighted, with examples such as liquid biopsy, glycoprofiling, extracellular vesicle profiling, and food and environmental analysis, alongside key challenges in reproducibility, standardisation, data interpretation, and clinical translation. In addition, selected non-plasmonic optical biosensing technologies are briefly discussed to position plasmonic biosensing within the broader landscape of multiplexed optical biosensing. This Feature Paper argues that the future of multiplexed plasmonic biosensing will depend less on further improvements in sensor performance than on robust, standardised analytical systems.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.